Latest / CME Outfitters Medical Education / A CaseWise™ Webcast – CIDP in Focus: Advancing Precision Across the Patient Journey from Early Recognition to Downstream Management
Transcript
- 0:00SPEAKER_09: Hi everyone, I'm Dr.
- 0:02SPEAKER_09: Jeff Allen, and I'm pleased to welcome you to CIDP in Focus, Advancing Precision Across the Patient Journey from Early Recognition to Downstream Management.
- 0:11SPEAKER_09: This activity is provided by CME Outfitters, supported through an independent educational grant from Argenics.
- 0:18SPEAKER_09: In support of patient care, CME Outfitters is jointly accredited to provide interprofessional continuing education for the healthcare team.
- 0:27SPEAKER_09: Please note that we may be discussing products or devices that are not currently labeled for use by the FDA, and we'll disclose such discussions when applicable.
- 0:35SPEAKER_09: Finally, CME Outfitters has employed generative AI to help draft visual content.
- 0:40SPEAKER_09: All the content was subsequently reviewed for accuracy and balance and compliance.
- 0:46SPEAKER_09: So again, I'm Jeff Allen.
- 0:47SPEAKER_09: I'm a professor of neurology in Minneapolis, Minnesota.
- 0:51SPEAKER_09: I'm so delighted today to be joined by several colleagues, including Dr.
- 0:54SPEAKER_09: Shafiq Karam, who's who's here with me today.
- 0:57SPEAKER_09: Shafiq, you want to say a couple words?
- 0:59SPEAKER_02: Thank you, Jeff, and hello everyone.
- 1:01SPEAKER_02: Thank you for joining us.
- 1:02SPEAKER_02: I'm Shafiq Karam, I'm a professor of neurology and chief of the Noromasca Division at the University of Pennsylvania.
- 1:09SPEAKER_09: Thanks so much, Shafiq.
- 1:10SPEAKER_09: Next up, we've got Dr.
- 1:11SPEAKER_09: Luis Carral who will be joining us via pre-taped recordings due to the time difference between here and Barcelona.
- 1:19SPEAKER_09: So here's Luis.
- 1:21SPEAKER_00: My name is Luis Querol.
- 1:22SPEAKER_00: I am a neurologist and researcher based in the hospital of Santa Cruz and Pau in Barcelona, Spain.
- 1:30SPEAKER_00: I am a neurologist that is dedicated to the care and research of inflammatory neuropathies, particularly in the field of autoantibodies and other biomarkers that are useful for diagnosing and monitoring these disorders.
- 1:46SPEAKER_00: Thank you for having me here.
- 1:47SPEAKER_09: Yeah, thanks, Luis.
- 1:48SPEAKER_09: We'd love to have you here live with us tonight, but we'll take you any way we can.
- 1:52SPEAKER_09: So now to help provide perspectives beyond our core faculty, we've invited key opinion leaders, including Dr.
- 1:59SPEAKER_09: Chris Gable from Duke and Dr.
- 2:00SPEAKER_09: Elio Marks from Boston University to pry case commentary.
- 2:04SPEAKER_09: We'll also hear from several anonymous community and rural neurologists, clinicians, as well as to find out how GPT weighs in on some of the case studies.
- 2:13SPEAKER_09: And importantly, we'll hear directly from Angela Parris, who is a patient advocate who has been living with CIDP for many years and has graciously agreed to share perspectives from her own patient journey.
- 2:23SPEAKER_09: So we've got a few main learning objectives today, and we'll start with a brief introduction for Dr.
- 2:28SPEAKER_09: Carell, then launch into our cases.
- 2:30SPEAKER_09: We will be using ask for your participation with the audience response system, and we'll see the responses to the same questions for various neurology clinicians, from academic to community to rural based.
- 2:42SPEAKER_09: So now let's begin with a brief introduction from Dr.
- 2:45SPEAKER_09: Carroll in Barcelona to answer the first very fundamental question: what is CIDP?
- 2:53SPEAKER_00: What is CIDP?
- 2:55SPEAKER_00: And we know what it is from the clinical perspective, and traditionally we have assumed that this is in which demelination, segmental demelination, which is the image that you are seeing on the left, is the pathological hallmark of CDP.
- 3:15SPEAKER_00: And this is something that we have assumed that can be indirectly detected by the electrophysiology, which is the image of the right, the temporal dispersion of the potential, the low velocities, and all that.
- 3:31SPEAKER_00: We know that it's a disease that responds to immune therapies, particularly to humoral ones, and we know that there's uh several elements of the inflammatory response involved.
- 3:41SPEAKER_00: But in fact, CDP is an heterogeneous disorder.
- 3:44SPEAKER_00: And all these things that I'm just selecting here are not present in all patients.
- 3:49SPEAKER_00: So not all patients with CDP have clear pathological demarination.
- 3:55SPEAKER_00: In not all patients, a response to immune therapies and humor therapies happens, and the mechanisms that are involved in each specific patient probably differ from one to another.
- 4:06SPEAKER_00: So CDP is a syndrome, it's an heterogeneous disorder, an umbrella term that captures different uh pathogenesis, different clinical presentations, and different um complementary studies.
- 4:21SPEAKER_00: Another thing important in the diagnosis of CDP is that, as I mentioned before, this is an heterogeneous disorder, and there are many different uh ways of presenting uh within the spectrum of CADP, and this means that there are also many different disorders that can mimic these many different presentations.
- 4:43SPEAKER_00: So we can have disorders of infectious uh origin, other autoimmune neuropathies, other um neoplastic or other conditions that can also be um uh mirror mimicking uh CDP.
- 4:57SPEAKER_00: And uh considering that there are different etiologies also in these uh mimics, we need to be extra careful uh when we do the differential diagnosis in C ADP.
- 5:10SPEAKER_00: And and this is um uh probably the most important part in the CDP process uh of care.
- 5:19SPEAKER_00: Uh the uh diagnostic part and particularly the uh being uh careful with the red flags and with the differentials.
- 5:28SPEAKER_09: Thanks, Luis, for that outstanding overview of CADP and some mimics and red flags.
- 5:33SPEAKER_09: And we'll talk more about some of those like red flags, electrodiagnostic criteria, and supportive studies on the other side of our first case.
- 5:40SPEAKER_09: Um but let's get into that first case, which is going to discuss some elements about diagnosis.
- 5:45SPEAKER_09: So I'm gonna turn it over to Shafiq to walk us through this case.
- 5:49SPEAKER_02: Thank you, Jeff.
- 5:50SPEAKER_02: Our patient is Victor.
- 5:52SPEAKER_02: Um he's a 52-year-old warehouse supervisor.
- 5:56SPEAKER_02: He's being evaluated for progressive weakness, numbness, and unsteadiness.
- 6:01SPEAKER_02: His symptoms progressed without plateau or relapsing pattern.
- 6:05SPEAKER_02: He does not have any antecedent illness, diarrheal episode, or vaccination.
- 6:11SPEAKER_02: And initially he started having difficulty rising from a chair and climbing stairs.
- 6:17SPEAKER_02: Now he is also tripping on uneven ground.
- 6:20SPEAKER_02: In the past three weeks, he reports that he has trouble with buttons and turning a key.
- 6:25SPEAKER_02: He has numbness in both feet, has ascended to his midcalf.
- 6:30SPEAKER_02: He does not describe any prominent pain.
- 6:34SPEAKER_02: There's no autonomic symptoms such as orthostatic lightheadedness, change in bowel and bladder function, abnormal sweating.
- 6:44SPEAKER_02: He does not report any shortness of breath, double vision, trouble speaking, or swallowing.
- 6:50SPEAKER_02: There's no weight loss rash or artralgia.
- 6:53SPEAKER_02: There's no family history of neuropathy, and he does not have diabetes, he drink alcohol in a minimal fashion, and there's no relevant medication or toxin exposure.
- 7:04SPEAKER_02: He has been already evaluated twice and was told each time that he probably has a pinched nerve.
- 7:11SPEAKER_02: And now he's worried about keeping his job.
- 7:15SPEAKER_02: When you examine Victor, he has uh both proximal and distal weakness, as you can see here.
- 7:22SPEAKER_02: His shoulder abduction is four out of five, hip flexion four outfive, ankle dose flexion four out of five, and finger abduction four plus out of five.
- 7:32SPEAKER_02: He has reduced vibration sensation and proprioception to the mid-calf and is reduced to the ankles.
- 7:40SPEAKER_02: The reflexes are absent at the ankles and reduced at the knees and biceps.
- 7:46SPEAKER_02: His gait is white-based, he's unable to tend them, and he has a positive rhomberg.
- 7:52SPEAKER_02: There's no tremor, no cranial nerve involvement, and his respiratory examination is normal.
- 7:58SPEAKER_02: You calculate an adjusted in cat score, which is three, his eye rods is in the 42nd percentile, and his grip strengths is 18 kilograms on the right and 20 kg on the left.
- 8:15SPEAKER_02: So you perform nerve conduction study or electrodiagnostic studies.
- 8:20SPEAKER_02: You are careful that the temperature limb is controlled and there's adequate distal stimulation, and you find that the left ulnar nerve have a prolonged distal latency more than 50% above the upper limit of normal, which would fulfill one of the criteria for demalnation according to the 2021 EANPS electrodiagnostic criteria.
- 8:44SPEAKER_02: You won't find any conduction block or temporal dispersion, unfortunately.
- 8:49SPEAKER_02: And the F waves are absent in both peronial nerves, which can suggest demallination.
- 8:56SPEAKER_02: But because the lower limit of uh or the peronial distal CMAP amplitude is less than 20% of the lower limit of normal, that does not quite fulfill the NPNS criteria.
- 9:10SPEAKER_02: He has absent sensory responses in both sural and both median nerves, and the net result is basically that you have only one nerve that would meet the demalination criteria.
- 9:23SPEAKER_02: You perform an SPEP with immune fixation, it's negative, there's no paraprotein.
- 9:28SPEAKER_02: You check the hemc, which is 5.4%, and that is normal.
- 9:33SPEAKER_02: His B12, TSH, and creatinine are also normal.
- 9:37SPEAKER_02: You check an ANA, it was negative, and the CSF protein has not been checked yet or CSF examination, and the nodal and parinodal antibody have not been sent yet.
- 9:52SPEAKER_02: So, in summary, this patient, Victor, he would meet the clinical criteria for typical CIDP because he has proximal and distal weakness in the upper and lower limbs with absent and reduced reflexes throughout an abromosensory examination.
- 10:08SPEAKER_02: It's been progressing more than eight weeks.
- 10:10SPEAKER_02: But because only one nerve meets a demal nation criteria, you classify Victor as having possible CIDP.
- 10:19SPEAKER_09: Thanks so much, Shafiq.
- 10:21SPEAKER_09: So at this point, we'd love to get the audience involved to see what you think about this case.
- 10:25SPEAKER_09: And we also want to hear from some of our TOLs, our community neurologists, our rural clinicians, and also our patient advocate.
- 10:32SPEAKER_09: So here's our first question about the case that Shafiq just outlined.
- 10:37SPEAKER_09: Yeah, and we'd love to get your responses on this.
- 10:39SPEAKER_09: So this patient's clinical picture fits CIDP, but the electrodiagnostic studies are only weakly supportive.
- 10:45SPEAKER_09: So the question is what do you do next?
- 10:47SPEAKER_09: Yeah, and the options are: would you like to repeat or extend the nerve conductions, look at proximal segments, look at additional nerves or contralateral sites?
- 10:56SPEAKER_09: Would you instead like to do other diagnostic tests like an ultrasound or an MRI?
- 11:02SPEAKER_09: Would you like to just go ahead and start treatment with IVIG, uh, empiric IVIG treatment?
- 11:07SPEAKER_09: Yeah, assuming you have the diagnosis right.
- 11:10SPEAKER_09: Or is your next move to refer to a neuromuscular expert, perhaps somebody in that uh one of the GPS CAP centers are excellent?
- 11:19SPEAKER_09: Or are you really not sure?
- 11:38SPEAKER_09: All right, looks like we have quite a few different responses here, some some mixed responses.
- 11:43SPEAKER_09: Maybe the highest one is make a referral or not, not really sure.
- 11:47SPEAKER_09: Um, Shafiq, I'd love to take get your thoughts on this, but before I hear your opinions, let's go to some of our KOLs, you know, starting with Dr.
- 11:54SPEAKER_09: Gable.
- 11:55SPEAKER_09: Dr.
- 11:55SPEAKER_09: Gable, what do you think about this case?
- 11:57SPEAKER_01: In this situation, because you have a clinical phenotype that looks like CADP, electrodiagnostics testing that looks uh weakly supportive, the next step is to look for other supportive testing.
- 12:08SPEAKER_01: And so in this case, I would look for actually imaging studies, which are part of the supportive testing.
- 12:16SPEAKER_01: You could choose uh spinal fluid imaging studies, you could choose an empiric uh treatment, uh, potentially as response to treatment is considered one of the supportive uh criteria as well for the diagnosis.
- 12:29SPEAKER_01: But typically you're looking for two of those supportive criteria to help support the diagnosis of CADP.
- 12:34SPEAKER_01: So I think I would start with looking for imaging uh first with obtaining a nerve ultrasound or MRA of the roots or plexus and hoping to see some focal enlargement in non-compressive sites, the cross-sectional area and the ultrasound, and then uh potentially nerve root enlargement or enhancement with the imaging on the MRA.
- 12:55SPEAKER_09: Right.
- 12:55SPEAKER_09: Now we're gonna get the opinion of Dr.
- 12:57SPEAKER_09: Mark's uh PU.
- 12:59SPEAKER_04: For this first decision point, it is a tough case, right?
- 13:03SPEAKER_04: Having only one nerve, a distal ulnar, uh a distal ulnar latency uh being prolonged isn't a typical place where where we see CIDP can be patchy and can often be more proximal.
- 13:18SPEAKER_04: Uh and yet there isn't a lot that can compress the ulnar nerve at this site.
- 13:24SPEAKER_04: Uh I would, as far as what I would do first, uh, that's always a tricky question because I often do a lot of things at the same time.
- 13:33SPEAKER_04: I think considering empiric IVIG is reasonable if only because the patient has been having progressive symptoms and it feels like we've given the patient enough time to progress where I want to make sure it's not gonna get any worse.
- 13:48SPEAKER_04: I don't want to have any secondary axonal loss that develops if we don't treat the demyelinating uh process quickly enough.
- 13:54SPEAKER_04: At the same time, I would probably order repeat nerve conduction studies, and this time I would add on some other less uh sampled nerves.
- 14:03SPEAKER_04: Oftentimes I'll add on the radial EIP compound motor action potentials in order to increase the uh uh catchment and try to find other nerves that can be demyelated.
- 14:17SPEAKER_09: Great.
- 14:17SPEAKER_09: Yeah, so we're thinking about doing more electrodiagnostics, we're thinking about imaging, we're thinking about the role of treatment.
- 14:22SPEAKER_09: So, how about our community providers?
- 14:25SPEAKER_09: Here we've employed avatars to provide spoken responses to match the actual clinical responses we received in writing.
- 14:32SPEAKER_09: And we'll start with a young neurologist that's got about five years of clinical experience.
- 14:39SPEAKER_03: I would begin treatment with IVIG first.
- 14:42SPEAKER_03: Clinically, the patient has a non-length-dependent neuropathy, which involves symmetric, proximal, and distal arm and leg weakness and hyperreflexia progressing over more than 10 weeks, and had has an electrodiagnostic study supportive, but not diagnostic of a primary demyelinating process.
- 15:05SPEAKER_03: Clinically, this is most likely to be CIDP, and I am worried that after two outside evaluations, the patient will continue to progress and could be at risk of permanent axonal damage if he is not treated promptly.
- 15:21SPEAKER_03: Practically speaking, treatment should not be delayed while we wait for an EMG.
- 15:27SPEAKER_03: While the patient starts therapy, I would arrange for them to have a repeat EMG for me so that I could attempt to more fully establish the diagnosis.
- 15:37SPEAKER_03: At this point, I would not send nodal and paranodal antibodies, as weakness is mild and there are no clinical features or lack of response to CIDP that would suggest that.
- 15:52SPEAKER_09: Okay, and next up, we're going to talk to a community neurologist with over 30 years of experience.
- 15:59SPEAKER_07: This patient meets the clinical criteria for typical CIDP.
- 16:03SPEAKER_07: What I don't have is electrophysiology that matches.
- 16:06SPEAKER_07: One nerve meets one demyelinating criteria.
- 16:09SPEAKER_07: Under the 2021 EANPNS framework that lands him at possible CIDP.
- 16:14SPEAKER_07: I'm not inclined to keep testing my way towards certainty while he keeps losing function.
- 16:18SPEAKER_07: The guideline itself gives me the route.
- 16:20SPEAKER_07: Impossible CIDP, an objective response to IVIG, plasma exchange, or corticosteroid supports the clinical diagnosis.
- 16:28SPEAKER_07: So that is the path I take.
- 16:30SPEAKER_07: I begin empiric IVIG, and I let the treatment response do the diagnostic work the electrophysiology could not.
- 16:40SPEAKER_09: Alright, next let's go to a rural neurologist with 45 years experience.
- 16:45SPEAKER_08: I don't perform these studies myself.
- 16:48SPEAKER_08: I rely on a colleague study and report, and that is exactly why I am careful with a result like this one.
- 16:53SPEAKER_08: What we have is a single nerve meeting, a single demyelinating criterion, the left ulnar, with a distal motor latency more than 50% above the upper limit of normal.
- 17:03SPEAKER_08: In forty-five years of practice, I have learned that a one-time abnormality can be an error.
- 17:08SPEAKER_08: I repeat things.
- 17:09SPEAKER_08: I will repeat a blood test that doesn't fit the patient in front of me, and I will certainly repeat a study that is carrying a diagnosis by itself.
- 17:16SPEAKER_08: I am not committing this patient to treatment on the strength of one nerve.
- 17:24SPEAKER_09: As we have a couple of opinions here, some favoring starting treatment, some favoring getting more uh diagnostic evidence, usually in the form of stronger electrodiagnostic studies, you know, as part of this project.
- 17:35SPEAKER_09: We pulled an additional four additional community neurologists who all voted to repeat or extend the nerve conduction study, including proximal nerve, other nerve segments, contralateral nerves.
- 17:45SPEAKER_09: Yeah, so for what that's worth, we got more responses to take a little bit of a bit of a deeper look from a nerve conduction standpoint.
- 17:53SPEAKER_09: We also know that AI has become a resource both patients and professionals are frequently turning to, and we thought it might be interesting to see how ChatGPT weighs in on this case.
- 18:02SPEAKER_06: I am a voiced version of how ChatGPT version 5.6 would manage this patient.
- 18:07SPEAKER_06: I would choose A.
- 18:08SPEAKER_06: Repeat or extend the nerve conduction studies, including proximal and additional nerve sites.
- 18:14SPEAKER_06: Here's why.
- 18:15SPEAKER_06: Victor has a very convincing clinical phenotype for typical CIDP, including progression beyond eight weeks, symmetric proximal and distal weakness, sensory loss, and reduced reflexes.
- 18:27SPEAKER_06: However, only one motor nerve currently fulfills a demyelinating criterion.
- 18:32SPEAKER_06: I would therefore strengthen the electrodiagnostic evidence before jumping to a treatment response as a diagnostic test.
- 18:39SPEAKER_06: The EAN PNS guideline specifically notes that examining additional nerves in proximal sites can improve sensitivity and recommends repeat testing when initial studies do not meet criteria.
- 18:51SPEAKER_06: CSF and imaging may subsequently provide supportive evidence.
- 18:55SPEAKER_06: I would reserve nodal and parinodal antibody testing for situations with clinical features suggesting an autoimmune nodopathy.
- 19:05SPEAKER_09: GPT weighs in.
- 19:06SPEAKER_09: So finally, let's hear from Angela Paris, who is a patient with CIDP, will share part of her diagnostic journey.
- 19:14SPEAKER_09: So Angela.
- 19:15SPEAKER_05: I remember my first EMG in 2015.
- 19:19SPEAKER_05: And just prior to that, I was swimming laps an hour, hour and a half each day was my recluse for my children.
- 19:27SPEAKER_05: And I always said the water was the only place that you could find peace and quiet.
- 19:31SPEAKER_05: And I started having trouble, difficulty swimming.
- 19:35SPEAKER_05: And I didn't, I didn't, couldn't figure it out.
- 19:39SPEAKER_05: And then when I was having my EMG, the doctor came in and said that he wanted to test my arms.
- 19:44SPEAKER_05: And I said, I don't have any trouble with my arms.
- 19:47SPEAKER_05: And when I lied down, I it all of a sudden dawned on me that I was struggling with my arms.
- 19:54SPEAKER_05: And then they came back and told me I had CIDP.
- 19:58SPEAKER_05: And um I asked for a second opinion and saw uh a physician who is listed as someone who has a Center of Excellence certificate.
- 20:09SPEAKER_05: And he said I did not have CIDP.
- 20:13SPEAKER_05: He thought maybe I was having postpolio or um something like that.
- 20:18SPEAKER_05: So it's very confusing.
- 20:19SPEAKER_05: It was a difficult six months for me.
- 20:23SPEAKER_09: All right, great.
- 20:24SPEAKER_09: And finally, we're gonna go back to Barcelona and see what Dr.
- 20:27SPEAKER_09: Carell thinks.
- 20:30SPEAKER_00: Thank you, Jeff, for this question.
- 20:32SPEAKER_00: So what I would do uh in this case uh is uh probably uh option A, which is repeat or extend the nerve conduction studies.
- 20:41SPEAKER_00: So this case has uh one clear demaginating criteria, and then it has some hint uh of demagination with the absence of the F-waves, although we cannot uh take that uh criterion formally because uh the nerves do not fulfill the criteria of amplitude, but it means that these nerves can give us more information regarding um the disease.
- 21:06SPEAKER_00: And probably if we extend the study of the nerves, uh we will be able to find other demalinating criteria in other nerves.
- 21:13SPEAKER_00: So that's probably what I would do first, which uh uh maybe also in parallel of doing maybe something else, like for example, an ultrasound or MRI, that can uh provide complementary information regarding these uh demalination status.
- 21:28SPEAKER_09: Great.
- 21:29SPEAKER_09: So we got a few thoughts here.
- 21:30SPEAKER_09: Shafiq, I want to give you a chance to weigh in here.
- 21:32SPEAKER_09: What what are your thoughts about the the next moves in this case?
- 21:36SPEAKER_02: Yeah, I think we've had we've heard great answer, and I don't think there's necessarily a wrong answer.
- 21:41SPEAKER_02: Um definitely having more uh nerve conduction study and trying to fulfill the criteria that's great.
- 21:47SPEAKER_02: But also there's nothing wrong in trying empiric treatment because as you know, you can upgrade from possible CIDP to CIDP if you do have uh an objective response treatment.
- 22:00SPEAKER_09: Agree.
- 22:00SPEAKER_09: It sounds like most people felt a little uncomfortable with the diagnosis, but also kind of that urge to start a treatment before disease worsening.
- 22:07SPEAKER_09: So some combination, often in tandem, of strengthening that diagnosis, either with imaging or nerve conductions, which would be what I would do, you know, by having that treatment quickly behind it.
- 22:20SPEAKER_09: Once you're satisfied with the diagnosis, seems to be an approach that many people were agreeing on, or at least close to agreeing on.
- 22:29SPEAKER_09: So if we kind of tally up everybody that's that's voted here, we can kind of we can see that the seven votes to repeat or extend the nerve conduction studies.
- 22:37SPEAKER_09: We got one vote for ultrasound or imaging, three votes to start empiric treatment.
- 22:42SPEAKER_09: Um Shafiq, does this does this surprise you or is this in line with the way you think about it?
- 22:49SPEAKER_02: I I think all of these are correct.
- 22:51SPEAKER_02: Um I agree.
- 22:53SPEAKER_09: Yeah, I do too.
- 22:54SPEAKER_09: And I think it kind of speaks to the challenge of the disease, really trying to define it and understanding what the next best step is.
- 23:01SPEAKER_09: But the the key message here is really be confident of your disease based on the phenotype, based on the diagnosis to work up, and understand the treatments and uh avoiding delays in treatment is really, really important as well.
- 23:14SPEAKER_09: So now before we continue with our case, let's take a brief look at the clinical criteria for CIDP, some red flags, electrodi testing, and supportive uh supportive studies.
- 23:25SPEAKER_09: Shafiq?
- 23:27SPEAKER_02: Yeah, so according to the EANPNS uh criteria that were updated in 2021, um, you have the typical CIDP and you have the variance.
- 23:36SPEAKER_02: So typical CIDP is when patients present with symmetric, proximal and distal, upper and lower limb weakness.
- 23:44SPEAKER_02: You also have to have sensory involvement in the two limbs or more, and the symptoms have been should be progressive or relapsing uh over eight weeks.
- 23:54SPEAKER_02: Okay, and unexamined the reflexes should also be either absent or reduced throughout.
- 24:01SPEAKER_02: But we also know that there are variants, and the variants are actually typically more difficult to present, so it's very important to keep them in mind.
- 24:10SPEAKER_02: Now, most CIDP is typical, more than 50% actually, and a lot of the variant eventually will progress to become typical CIDP.
- 24:20SPEAKER_02: But again, it's important not to miss them.
- 24:22SPEAKER_02: They do also have the eight-week duration, they do have the fact that they're progressive and relaxing, but in this case, the reflexes may be normal if you have an unaffected limb.
- 24:34SPEAKER_02: Um, probably the most common variant is the multifocal, and that also is called Lewis Sumner syndrome.
- 24:40SPEAKER_02: It presents in the mainly in the upper limb, but it can also present in the lower limb and an asymmetrical fashion.
- 24:47SPEAKER_02: Both motor and sensory symptoms are involved.
- 24:50SPEAKER_02: If not, then you think something else like multifocal motor neuropathy.
- 24:54SPEAKER_02: And then we have the motor CIDP, which is proximal and distal, upper and lower limb weakness without any sensory symptoms or sensory involvement on the nerve conduction study.
- 25:06SPEAKER_02: You have the pure sensory one where there's no motor involvement, but this the sensation is involved, patients have ataxia and paresthesia and so forth.
- 25:15SPEAKER_02: You have the multi, you have the distal, which people present with predominantly lower limb and mainly the feet uh weakness, and then you have the focal, which is again another one that can be difficult to prove to uh diagnose because patients present with only symptoms in one limb instead of uh the two or more.
- 25:39SPEAKER_02: Now looking at the uh diagnosis, you have to both be sure you're avoiding under-diagnosis, but also you want to avoid over-diagnosis.
- 25:52SPEAKER_02: So when you have proximal uh muscle weakness and a neuropathy phenotype, you have to consider CIDP on your main differential.
- 26:01SPEAKER_02: There's not a lot of neuropathy that would give you proximal weakness.
- 26:04SPEAKER_02: So I would put CIDP as one of the top ones.
- 26:07SPEAKER_02: And then duration is important, but also remember some CIDP patients can present acutely, and it can be very difficult to distinguish them from Guian-Berrin syndrome.
- 26:17SPEAKER_02: So when the patient progresses over eight weeks or keeps having relapse, then you have to change your diagnosis from GBS to CIDP.
- 26:25SPEAKER_02: On the same time, we do want to avoid overdiagnosis, and some of the red flags are listed here.
- 26:31SPEAKER_02: If the patient has significant pain, think about something else.
- 26:35SPEAKER_02: Autonomic features.
- 26:36SPEAKER_02: This is not classical.
- 26:37SPEAKER_02: And if they are present in CIDP, they're mild.
- 26:39SPEAKER_02: But if the patient has severe orthostatic hypertension and syncope and severe diarrhea and constipation, again, consider an alternative diagnosis.
- 26:48SPEAKER_02: Shortness of breath and cranial nerve involvement are not typical for CIDP.
- 26:53SPEAKER_02: Um, any systemic water retention, skin changes, weight loss, and so forth.
- 26:59SPEAKER_02: If there's family history, you should think about genetic condition.
- 27:03SPEAKER_02: If there's subacute presentation with low frequency tremor, market attacks and distal weakness, think about uh some of the autoimmune neuropathies.
- 27:12SPEAKER_02: And when the EA and BNS criteria are not fulfilled.
- 27:15SPEAKER_02: And I would add one, if there's no response to your treatment, you should really reconsider the diagnosis because most patients with CIDP will respond to the treatment that we will uh discuss later.
- 27:27SPEAKER_09: Thanks, Shafiq.
- 27:29SPEAKER_09: I think you know the most important thing to make the diagnosis is the clinical features of the disease.
- 27:34SPEAKER_09: You know, the second most important is probably the electrodiagnostic features.
- 27:38SPEAKER_09: The guideline splits out electrodiagnostic features into two basic categories: those that are strongly supportive of demyelination and those that are weakly supportive of demyelination.
- 27:47SPEAKER_09: All of the motor abnormalities are those that really indicate that there's a problem with myelin.
- 27:52SPEAKER_09: So we're looking at things like conduction velocity, slowing, motor conduction block, temporal dispersion, absent F-waves, prolonged distal motor latencies, yeah, and F-wave prolongation.
- 28:01SPEAKER_09: Essentially, to meet the highest level of criteria, you need two nerves with a predefined demyelinating change.
- 28:08SPEAKER_09: Yeah, just to, yeah, if you only have one nerve that you fit, then you would fulfill that criteria of weekly supportive of uh of demyelation.
- 28:16SPEAKER_09: And also it's important to find some degree of sensory abnormality, exception, of course, of the motor variant in which the sensory studies in its purest form should be spared.
- 28:26SPEAKER_09: In patients with weekly supportive criteria, then collecting supportive data may be helpful in order to strengthen your diagnostic confidence.
- 28:33SPEAKER_09: And we know there's a couple of buckets of supportive criteria that can be helpful.
- 28:37SPEAKER_09: One is imaging.
- 28:38SPEAKER_09: If you do an MRI, you might see enlargement or enhancement of nerve roots or other focal nerve segments.
- 28:44SPEAKER_09: Ultrasound can also be very helpful to look for enlargement in areas that might not be accessible on a nerve conduction study.
- 28:50SPEAKER_09: We know that spinal fluid protein elevations can be supportive of the diagnosis.
- 28:54SPEAKER_09: Although we don't do a lot of nerve biopsies anymore, if you were to do a nerve biopsy for cases that maybe they're like that's on the table, they might show characteristic uh chronic re-myelination or demyelination changes or some end of uh neural inflammatory infiltrates.
- 29:10SPEAKER_09: Another thing that's considered supportive of a diagnosis is an objective response to treatment.
- 29:15SPEAKER_09: So you start a treatment, somebody definitely gets better, that would be supportive of the uh of the disease.
- 29:21SPEAKER_09: Of course, each of these is considered supportive, and none of them should be considered diagnostic in isolation.
- 29:26SPEAKER_09: So it's always important to put all of these tests in the context of what the clinical picture picture is and what the electrodiagnostic studies show.
- 29:34SPEAKER_09: But yeah, if there's some confusion or ambuity, but your pretest probability is still relatively high, these can be helpful to strengthen your diagnosis.
- 29:43SPEAKER_09: They also might help you in a different way, yeah, which is also important.
- 29:47SPEAKER_09: So before we move on, we're gonna repeat the the polling question that we asked before and to see if anybody's mind has changed.
- 29:54SPEAKER_09: I won't read all of the the questions again, yeah, but they're all the same uh that we talked about previously.
- 30:21SPEAKER_09: So it looks like we've got a little bit of a shift, you know, where there's a lot more folks out there that are doing more nerve conductions and starting more treatment.
- 30:28SPEAKER_09: Uh people seem to be a little bit more confident, you know, less not knowing responses or referrals.
- 30:34SPEAKER_09: You know, so I think we're kind of lining up here uh on a on a path forward.
- 30:38SPEAKER_09: Uh Shafiq, any any other comments from you on this?
- 30:41SPEAKER_02: No, I totally agree.
- 30:44SPEAKER_09: Great.
- 30:44SPEAKER_09: Well, let's move on to our case.
- 30:45SPEAKER_09: Shafik, I'll pass it over to you to talk about Victor a little more.
- 30:49SPEAKER_02: Yeah, so Victor is started on IVIG.
- 30:52SPEAKER_02: He gets the loading dose, which is two gram per kilogram, and he gets the maintenance dose, which is one gram per kilogram, every three weeks.
- 31:01SPEAKER_02: He comes back eight weeks later and he says, Well, maybe I have a little bit more energy.
- 31:07SPEAKER_02: But then you ask him, Well, tell me some example that where you can tell me things that you were not able to do that you are able to do right now, and he cannot really identify any specific tasks, and his family does not feel that he really changed anything.
- 31:25SPEAKER_02: Uh, the good thing is that he has tolerated the infusion without adverse effect, and then you examine the patient and you don't see any changes, you calculate the adjusted ink score, it's still three, and this is the what it was the first time you saw him, and then his I rods is now 44th percentile, and the baseline was 42nd, so not a big change.
- 31:47SPEAKER_02: And for the grip strength, same thing: 18 kilogram on the right and 21 on the left, which is very similar to the first time you saw the patient before starting treatment, and there's no infusion-related adverse effect.
- 32:00SPEAKER_02: So the medication has been given consistently.
- 32:06SPEAKER_09: Don't have a lot of time to open this question up to for a general discussion, but I do want to hear from Luis to see what he thinks about Victor.
- 32:14SPEAKER_09: Yeah, Victor fears feels marginally better, nothing objective has changed, and there are several choices here to consider regarding what the next step would be.
- 32:22SPEAKER_09: So let's hear from Luis.
- 32:24SPEAKER_00: Thank you for the question.
- 32:25SPEAKER_00: Uh I think this is a very common situation in which a patient feels somewhat better subjectively, but we are unable to confirm that with formal scales.
- 32:35SPEAKER_00: And remember, this is a mandate that uh uh there is some objective form of response.
- 32:40SPEAKER_00: So we don't have that in this case.
- 32:43SPEAKER_00: Um so in I think after having this eight-week period of good treatment with good dosing and good frequency, uh, if we don't see a formal evidence of response, we have to consider this a non-response, a refractoriness to IVIG, and then uh probably reassess diagnosis, reassess the tests that have been done and confirm that in fact this is a CIDP.
- 33:08SPEAKER_00: And if that is the case, then uh maybe to some other um treatment and uh and go with that one.
- 33:15SPEAKER_00: But first thing uh is to revise the case, to review the diagnostic uh process and uh consider that uh there is no response to IVIG.
- 33:24SPEAKER_09: Thanks, Luis.
- 33:24SPEAKER_09: Shafik, what do you think?
- 33:25SPEAKER_09: Agree, disagree, other comments?
- 33:28SPEAKER_02: Yeah, I totally agree.
- 33:29SPEAKER_02: We really rely and we really need to see an objective response.
- 33:32SPEAKER_02: And you have completely unchanged INCAT, IROTs, grip strengths, and and your clinical examination.
- 33:39SPEAKER_02: And you we know that the majority of people who are going to respond to IVIG, meaning 90% plus, should have a response within six weeks.
- 33:48SPEAKER_02: Um, so having no response at eight weeks uh is a little bit concerning, and I would uh like to revisit the diagnosis at this point.
- 33:58SPEAKER_09: Yeah, I'm there with you.
- 33:59SPEAKER_09: I have a similar opinion.
- 34:01SPEAKER_09: Now let's do a little bit of a kind of a hypothetical what if type of question.
- 34:05SPEAKER_09: What if this same patient had a prominent postural tremor of the hands and weakness that's been more distal than proximal rather than both proximal and distal?
- 34:15SPEAKER_09: Would that change your workup?
- 34:16SPEAKER_09: Would a positive versus a negative nodal or perinodal antibody be something to think about?
- 34:21SPEAKER_09: I'm gonna ask you again, Shafiq, but before that, we'll go back to Barcelona and see what Luis has to say.
- 34:26SPEAKER_00: Yeah, this this uh what if uh this patient had a tremor or predominantly distal involvement?
- 34:34SPEAKER_00: Uh, I think that's a that's a good question.
- 34:36SPEAKER_00: So in this case, I am not sure that I would go uh for sure with the idea that this is an autoimmune odopathy for a couple of reasons.
- 34:46SPEAKER_00: Of course, it's something that we need to consider and we need to be aware that uh an autoimmunodopathy could fit into this phenotype.
- 34:54SPEAKER_00: But if we take, for example, the electrophysiology of this case, usually anthinerofascina 155 and other autoimmune nodopathies have very clear signs of the imagination.
- 35:05SPEAKER_00: Um they usually have uh very slow conduction velocities, very long latencies, which is not the case in this particular patient.
- 35:15SPEAKER_00: So that would not be completely typical of an autoimmunodopathy.
- 35:20SPEAKER_00: However, it's true that the phenotype, distal involvement predominant, the tremor, the absence of response to IVIG would qualify for what we consider red flags to check the uh nodoparanodal antibody.
- 35:33SPEAKER_00: So I guess yes, we have to be aware of these uh antibodies and order in these patients in particular, but uh if I had to bet on this patient, I wouldn't say it would have for sure an autoimmunodopathy.
- 35:48SPEAKER_09: Great Safik, what do you think?
- 35:50SPEAKER_02: Yeah, I would totally agree with Luis.
- 35:52SPEAKER_02: Um, you know, one thing to consider is of course the IgM and with the MAG antibody that could also present with uh distal predominantly symptoms and tremor and uh doesn't response, uh doesn't respond very well to IVIG.
- 36:09SPEAKER_02: So that would be another thing I would check for.
- 36:12SPEAKER_09: Yeah, totally agree.
- 36:13SPEAKER_09: It's a bit unusual for nodopathy, but some of those factors you can't get away from tremor treatment response or lack thereof.
- 36:20SPEAKER_09: You know, I'm probably checking for nodopathies at that point, even if the it's relatively low.
- 36:25SPEAKER_09: All right, so let's move on to our next case, our case two.
- 36:29SPEAKER_09: Uh so this case is a 45-year-old woman who will Diane, and she's a high school teacher.
- 36:34SPEAKER_09: Uh, she's been diagnosed with CADP of about eight, 18 months ago, and she presents for routine maintenance and follow-up.
- 36:42SPEAKER_09: She's been on IVIG since her diagnosis, but feels like she's she's kind of stuck.
- 36:46SPEAKER_09: She's better than she was before diagnosis, but she's um kind of at a place where she's not improving any any longer.
- 36:54SPEAKER_09: She walks without an aid but cannot run.
- 36:56SPEAKER_09: She drops small objects, she's unsteady in the dark and on uneven ground.
- 37:01SPEAKER_09: She's able to keep working full time, but raises and the treatment schedule uh um unprompted.
- 37:08SPEAKER_09: On her infusion days, she consumed her infusion days consume most of her working day.
- 37:13SPEAKER_09: She's got to travel 90 minutes each way in order to get to her infusion center.
- 37:17SPEAKER_09: And sometimes she struggles with her infusions.
- 37:20SPEAKER_09: She's got headaches after each infusion, and she uses PTO, paid time off for infusions, and that's kind of been running out.
- 37:28SPEAKER_09: So her question was whether there's anything that would be not required, not require her from a treatment standpoint, treatment standpoint to organize her life around her infusions.
- 37:38SPEAKER_09: Her neurologic examination shows weakness with distally in the lower limbs, with ankle dorsiflexion, and distal in the upper limbs as well, and her and her finger abduction.
- 37:49SPEAKER_09: Approximately her strength at this point is pretty good.
- 37:51SPEAKER_09: She's got reduced sensation, mainly to vibration, large fiber modalities distally, her gait is uh ataxic.
- 37:59SPEAKER_09: She doesn't need a gait aid to walk, but she's not very, very steady.
- 38:03SPEAKER_09: She's got reduced distal reflexes, no tremor, and no cranial involvement.
- 38:08SPEAKER_09: Wind cat score at this point is a two, yeah, which is pretty stable across the last and last year.
- 38:13SPEAKER_09: Her eye rods is the 58th percentile, and grip strength is 22 kilograms on the right and 24 kilograms on the left.
- 38:23SPEAKER_09: So her current treatment includes IDIG.
- 38:26SPEAKER_09: She gets a dose of one gram per kilogram every three weeks.
- 38:29SPEAKER_09: It's administered at an infusion center, which is again about a 90-minute drive for her.
- 38:34SPEAKER_09: She got it needs pre-medication for post-infusion headaches.
- 38:37SPEAKER_09: She does not take corticosteroids and she's not on any other immunosuppressive therapy.
- 38:43SPEAKER_09: So we've got another audience polling question here that we'd love to get your input on.
- 38:47SPEAKER_09: And the question for this case is what is the next most appropriate step?
- 38:51SPEAKER_09: Would you like to refirm, reconfirm the diagnosis and reassess for a mimic or a variant phenotype?
- 38:58SPEAKER_09: Is it more appropriate to verify that the dose and interval of her IVIG are adequate before changing anything?
- 39:04SPEAKER_09: Would you like to order nodal or parinodal antibody test?
- 39:08SPEAKER_09: Perhaps you'd like to reduce or stop IVIG and monitor for a clinical change.
- 39:13SPEAKER_09: Or would you like to maintain the current treatment regimen because the patient is stable or transition to a different maintenance therapy, you know, with a defined monitoring plan?
- 39:22SPEAKER_09: Or refer to a specialized center or not, really sure.
- 39:26SPEAKER_09: We'll give a little bit more time for responses to come in.
- 39:50SPEAKER_09: All right.
- 39:51SPEAKER_09: So here's what many of our polling uh audience thinks about maybe transitioning to a different therapy, you know, with a defined monitoring plan and followed by verifying that the dose is accurate before changing anything.
- 40:05SPEAKER_09: Shafiq, um, what are your thoughts on this?
- 40:07SPEAKER_09: What's your next move?
- 40:09SPEAKER_02: Yeah, I think I would agree with the majority.
- 40:10SPEAKER_02: It seems that while the drug uh or IVIG has worked for this patient, seems inconvenient uh and it's affecting uh life significantly.
- 40:21SPEAKER_02: So perhaps uh a different option would be uh should be attempted in this case.
- 40:27SPEAKER_09: You're probably doing a better job of mal uh balancing the efficacy of the drug and logistics and tolerability are certainly something to think about.
- 40:38SPEAKER_09: So let's go on to see what our or other members think, starting with Dr.
- 40:42SPEAKER_09: Gable.
- 40:43SPEAKER_01: I think that in this case, because there is a response to immunoglobulin, I would stay with immunoglobulin as a treatment, but I would offer uh a sub Q Ig therapy, of which there's a weekly and a monthly version, a variety to choose from.
- 41:00SPEAKER_01: Uh, and so uh that would reduce the burden of treatment that she's struggling with with respect to being able to work and continue her treatments.
- 41:09SPEAKER_01: And it also would minimize the side effects that she's having with respect to the headache that you often can get with IVIG, even with pre-medications.
- 41:17SPEAKER_01: And so there's a little less likelihood of that happening with a sub QIG.
- 41:20SPEAKER_01: Um, so I think that that would be a good option.
- 41:24SPEAKER_01: Um, and then to have uh shared decision making with discussing with a patient what um which uh version they would like, a weekly sub QIG versus a monthly um sub QIG.
- 41:33SPEAKER_01: I think um at this point, uh, because there is a response to immunoglobulin, I wouldn't reduce or stop it um because she could clinically worsen.
- 41:46unknown: Great.
- 41:46SPEAKER_09: So now we're gonna hear from Dr.
- 41:48SPEAKER_09: Marx.
- 41:49SPEAKER_04: In this case, uh it's tricky because the question is what is the appropriate next step?
- 41:54SPEAKER_04: And oftentimes we're doing a few things at the same time.
- 41:57SPEAKER_04: That being said, I would probably prioritize reconfirming the diagnosis.
- 42:03SPEAKER_04: Uh I would like to see a repeat nerve conduction study.
- 42:07SPEAKER_04: And the reason is because many times these patients who have a primary demyelinating uh condition like CIDP, because of that inflammatory process around the nerves, can develop secondary axonal loss.
- 42:20SPEAKER_04: And a big reason why a lot of these patients don't respond to IVIG therapy or to other immunomodulatory therapies is because they were diagnosed late enough or have aggressive enough disease that the axons themselves have been injured.
- 42:36SPEAKER_04: And once you've injured the axons, it's really hard to recover function, much more so than if you have only demyelinating disease.
- 42:47SPEAKER_09: All right, and how about our practicing neurologist with five years experience represented by an avatar?
- 42:54SPEAKER_03: Right now the patient is clinically stable and able to work, but her treatment poses major barriers to her lifestyle.
- 43:03SPEAKER_03: I would propose switching her to subcutaneous IG, which is probably less likely to cause side effects, and which she could do more quickly at home.
- 43:12SPEAKER_03: This might also allow us to increase the dose of IG as well, which she might benefit from since she still has some mild disability.
- 43:21SPEAKER_03: I would not transition her to Fgarty Gimod, as I do not consider her completely stable given her INCAT score, and there are some case series, and I have some anecdotal evidence from friends of patients with CIDP deteriorating after switching from IVIG to an FCRN inhibitor.
- 43:44SPEAKER_09: Next up, we'll hear from our neurologist in the community with 30 years experience.
- 43:56SPEAKER_07: The dose, the interval, and whether she is in fact receiving what is written in the chart.
- 44:01SPEAKER_07: And I'll be honest that this is a difficult one, precisely because she is doing well.
- 44:05SPEAKER_07: So the next thing I do is sit down and discuss the circumstances with her plainly, what we know with confidence and what we don't.
- 44:12SPEAKER_07: That conversation is how we get to the benefit she actually wants, which is to keep working.
- 44:19SPEAKER_09: All right, and our rural neurologist uh with forty-five years of practice again represented by an avatar.
- 44:27SPEAKER_08: When someone has been on infusions for a long stretch, my instinct is to satisfy myself that we are not treating the wrong disease.
- 44:34SPEAKER_08: Nodal and paranodal antibodies are what I want to see, because an autoimmune nodopathy does not behave like CIDP and does not respond to immunoglobulin the way CIDP does.
- 44:44SPEAKER_08: If I could not find that testing in the record, I would send it before I touched anything else.
- 44:49SPEAKER_08: The other question I would normally want answered is whether she still needs the infusions at all.
- 44:53SPEAKER_08: I don't like treating anyone indefinitely without testing that assumption.
- 44:56SPEAKER_08: My instinct is always to pull back and see what happens.
- 45:02SPEAKER_09: As was the case with our other series, we asked a number of other community neurologists of this same question, and this is how they responded.
- 45:10SPEAKER_09: Three indicated that they would maintain immunoglobulin, you know, but switch to subcutaneous Ig, and we heard a couple of responses from our panel on that option.
- 45:19SPEAKER_09: And one of the four would like to transition to a new therapy and mainly an FCR inhibitor.
- 45:25SPEAKER_09: So before moving on, I want to hear from ChatGPT and what uh what an AI model might do in this case.
- 45:32SPEAKER_06: I am a voiced version of how ChatGPT version 5.6 would manage this patient.
- 45:38SPEAKER_06: I would choose D, reduce or stop IVIG, and monitor carefully for clinical change.
- 45:44SPEAKER_06: Diane is stable, but stability does not necessarily tell us whether her disease is still active or whether she remains treatment dependent.
- 45:52SPEAKER_06: She has been on IVIG for 18 months, and her adjusted INCAT has been unchanged for a year.
- 45:58SPEAKER_06: In a clinically stable patient, the EAN PNS guideline recommends periodically testing the ongoing need for IVIG by reducing the dose, lengthening the treatment interval, or discontinuing treatment with objective monitoring.
- 46:11SPEAKER_06: I would therefore perform a structured de-escalation, not simply stop treatment and hope for the best using NCAT, IRODs, strength, and the patient's functional abilities as benchmarks with a predefined rescue plan if she worsens.
- 46:26SPEAKER_06: That would tell us whether treatment dependence persists before committing her to another long-term therapy.
- 46:34SPEAKER_09: All right, and Shafiq, I'm coming to you soon, but first we're going to go back to Barcelona.
- 46:39SPEAKER_00: So thank you again for this question.
- 46:40SPEAKER_00: I I think this is also a very common situation, particularly for us at reference centers.
- 46:46SPEAKER_00: You receive a patient that is already on treatment and uh it's not doing completely well.
- 46:52SPEAKER_00: Uh so first thing I would do with this case, I think it's clear, which is um it's a B, which is uh revised that the immunoglobulins are being administered at the correct dose and frequency.
- 47:07SPEAKER_00: Uh, because first thing is if we have a patient that has responded to immunoglobulins, uh it means uh that maybe there's some room for extra improvement if the dosing and frequency are not completely optimized.
- 47:23SPEAKER_00: So that to me probably would be the first thing to do, uh, on top of revising the diagnosis and everything.
- 47:29SPEAKER_00: But assuming that the diagnosis is correct, that's probably the first thing that I would do.
- 47:34SPEAKER_00: And if that's correct and that's uh perfectly uh set, then then maybe select for another treatment.
- 47:42SPEAKER_00: But uh first thing is revise the dosing and regimen of IVAG.
- 47:49SPEAKER_09: We got a few responses.
- 47:50SPEAKER_09: Uh Safik, you want to weigh in on this one?
- 47:53SPEAKER_02: Yeah, I think again, there's no completely wrong answer here.
- 47:57SPEAKER_02: I agree that um obviously the patient is struggling uh with the infusion specifically, and there's our residual.
- 48:05SPEAKER_02: And as we know, patients with CIDP, unfortunately, a lot of time can have permanent residual.
- 48:10SPEAKER_02: And the question, has the response to treatment been optimal or not?
- 48:14SPEAKER_02: And uh is there room to improve things further or not?
- 48:17SPEAKER_02: And unfortunately today, the main way is to do is to change treatment or increase the dose of IVIG, which obviously would not be necessarily convenient in this case.
- 48:27SPEAKER_02: Um and then uh I would agree that the disease could be completely inactive and there's no point in treating.
- 48:34SPEAKER_02: So a few things that we need to do.
- 48:36SPEAKER_02: Uh I would sit with this patient and discuss different options and see what would work best.
- 48:40SPEAKER_02: Obviously, sub QIG would be a great transition.
- 48:43SPEAKER_02: If the disease is still active, it's more convenient.
- 48:46SPEAKER_02: Um, an FCRN would be also an alternative option.
- 48:50SPEAKER_02: Maybe the patient would have more improvement with a different therapy, um different mechanisms of action.
- 48:56SPEAKER_02: Uh, but at the same time, there could be worsening, as somebody mentioned.
- 49:00SPEAKER_02: So all of these things should be discussed clearly with the patient and expectation and potential risk and so forth.
- 49:09SPEAKER_09: Great.
- 49:10SPEAKER_09: So this was our tally of all of our responses.
- 49:12SPEAKER_09: We had one to confirm, reconfirm the diagnosis and assess for a mimic.
- 49:16SPEAKER_09: We had a couple of responses to verify the dose and interval before changing.
- 49:20SPEAKER_09: One clinician wanted nodal and parinodal testing, uh, somebody else would reduce or stop the IVIG.
- 49:27SPEAKER_09: We had the majority of people, five clinicians, uh, elected to uh maintain the current uh program because the patient's stable, but switch from IVIG to subcutaneous Ig, and one thought about switching to a different therapy, uh perhaps an FCRN.
- 49:42SPEAKER_09: Um my approach for somebody like this is generally to really figure out what we're doing.
- 49:46SPEAKER_09: So confirm that the treatment is accurate and it's what we think it is.
- 49:51SPEAKER_09: Yeah, if that all looks good, yeah, so response B, yeah, then move in to try to understand disease activity.
- 49:57SPEAKER_09: Often that means delaying or or prolonging treatments, and then if uh disease activity is established and thinking about alternative treatments that can better balance the tolerability.
- 50:09SPEAKER_09: Often that means subcutaneous Ig in a case like this.
- 50:12SPEAKER_09: Um, but there's a number number of different options, options to go.
- 50:16SPEAKER_09: So let's uh take a reassessment of Diane's case or case two.
- 50:20SPEAKER_09: So she uh remember had definite CIDP according to the guidelines.
- 50:24SPEAKER_09: Uh, she had antibody nodal perinol antibody testing and an SPEP that was negative.
- 50:29SPEAKER_09: No other alternative diagnosis was identified.
- 50:32SPEAKER_09: She had an objective response to IBIG and initiation, in cat improved from four to two, and her I rods from 31 to 58.
- 50:39SPEAKER_09: Her IVIG was already been optimized at a gram per kilogram every three weeks, and two prior attempts to extend the interval to every four weeks resulted in clear and objective worsening with a drop in her NCAP from two to three, which recovered when she went back to every three-week dosing.
- 50:56SPEAKER_09: She increasingly had difficult peripheral venous access.
- 50:59SPEAKER_09: You know, she needed multiple sticks each time she was trying to get her infusion, and each infusion lasted multiple hours, five to six hours.
- 51:06SPEAKER_09: You know, headaches were becoming a problem.
- 51:08SPEAKER_09: She needed pre-medications.
- 51:10SPEAKER_09: Uh she had trouble maintaining her lifestyle at work, but one of her goals was to keep working and stay organized around her infusion schedule.
- 51:18SPEAKER_09: And even with that, she had residual distal weakness and ataxia that was attributed to exonal loss and unchanged over the prior prior month.
- 51:27SPEAKER_09: So let's talk about uh this in a little bit more detail.
- 51:31SPEAKER_09: So we're here, we have a question for our faculty.
- 51:34SPEAKER_09: The dose and the interval are confirmed to be adequate, the diagnosis seems to be secure, the disease seems to be active based on our treatment withdrawal and deterioration and then improvement when IVIG went back.
- 51:46SPEAKER_09: Yeah, and the real issue is the burden of the treatment.
- 51:48SPEAKER_09: So I want to hear from Luis about what he might think step in this case would be.
- 51:56SPEAKER_00: Yeah, again, thank you for this question.
- 51:58SPEAKER_00: I think it's another very common situation.
- 52:01SPEAKER_00: Um, we many times have these patients that in fact have um responded to IVIG, but the burden of the of the treatment is quite important.
- 52:13SPEAKER_00: And then we are faced with the dilemma of whether to be okay with this treatment and just find a way to make it less burdensome or to change the treatment completely.
- 52:27SPEAKER_00: And I think in this case, which still has significant disability, um, maybe uh keeping the same type of treatment with immunoglobulins but using a different uh route of administration could be an option.
- 52:43SPEAKER_00: But I think we have to be more ambitious probably now, and maybe I would try something new, something else first, and I would in this case choose C, transition to uh an FCR antagonist, and then uh be uh be very careful with the follow-up in the upcoming weeks to see if the patient improves or relapses.
- 53:05SPEAKER_00: Uh, but I think I would give an opportunity to something new, and if uh and if in this case it doesn't work, then I would maybe go back to the immunoglobulins and then find a more uh convenient way of administration, like subcutaneous immunoglobulins or something like that.
- 53:22SPEAKER_00: But first I think I would try something new, like FCRN antagonists.
- 53:27SPEAKER_09: Rachik, anything briefly to add to that?
- 53:30SPEAKER_02: No, I think both uh B and C would be fine.
- 53:34SPEAKER_09: Yeah, I think I agree with that.
- 53:35SPEAKER_09: Let's see what Angela thinks, our patient uh representative.
- 53:40SPEAKER_05: Well, I started on IVIG, and I was getting IVIG every three weeks, and it was taking uh six to eight hours to administer it.
- 53:52SPEAKER_05: And I knew that the IVIG was doing what it was supposed to do, which was slowing down the progression.
- 53:59SPEAKER_05: Because I was on the foundation website all the time, they spoke about um Sub Q, and I brought the Sub Q to my neurologist and asked him if I would be a good candidate, and he thought that I would be.
- 54:13SPEAKER_05: And so I started SubQ um in 2018, and of course, what a relief not to have to go down to an infusion center.
- 54:29SPEAKER_05: I really wish I had started a lot sooner because I have seen a significant improvement um in the past year.
- 54:38SPEAKER_05: It has given me my life back.
- 54:42SPEAKER_09: All right.
- 54:42SPEAKER_09: And so one last what-if question.
- 54:45SPEAKER_09: What if this patient's nodal and perinodal antibodies came back positive?
- 54:48SPEAKER_09: We're gonna ask Luis if that would change his approach or treatment or management of this patient.
- 54:53SPEAKER_09: Uh Luis?
- 54:55SPEAKER_00: So that's a good question.
- 54:56SPEAKER_00: And and it's true that um that for patients with these antibodies, we would love to be able to use FCRN antagonists, for example, the same way we we can offer this to regular CDP patients.
- 55:12SPEAKER_00: Uh, currently this is not approved.
- 55:14SPEAKER_00: Uh uh, and uh this doesn't mean that it doesn't make sense to use it.
- 55:18SPEAKER_00: Uh um I think uh there is evidence in the trial, in the ADO trial, to support that these patients, the ones with uh the autoantibodies, can behave better uh with um with F-Gartigimode.
- 55:33SPEAKER_00: Uh so we cannot recommend this um openly because the label doesn't allow for that.
- 55:40SPEAKER_00: But if in a case with an out-immunodopathy we think that uh that the best treatment can be an FCR antagonist, I think we have some data coming from the Adir trial that really support this.
- 55:53SPEAKER_09: Great.
- 55:53SPEAKER_09: Now, before we wrap up, let's briefly look at our current treatment on the mentarium for CIDPs, looking at some both conventional therapies and some newer agents.
- 56:02SPEAKER_09: Shafiq, I'm gonna turn it over to you to walk some of the conventional therapies, then I'll jump in for some of the newer therapies.
- 56:10SPEAKER_02: Yeah, so right now the first line therapies that are recommended, the EANPS uh in 2021, are uh as initial IVIG plasma exchange steroids.
- 56:21SPEAKER_02: All of those you can use them as maintenance, uh, but as a maintenance, you can also use subcutaneous or facilitation.
- 56:29SPEAKER_02: Most people will respond to these treatments, by the way.
- 56:32SPEAKER_02: So it's very important if the patient doesn't respond to reconsider the diagnosis.
- 56:37SPEAKER_02: Um, and each of these medications comes with this pros and cons.
- 56:41SPEAKER_02: Steroids have a lot of side effects, especially long-term IVIG is can be inconvenient, need venous access, has wearing off effect, and so forth.
- 56:52SPEAKER_02: But all of these medications have been studied extensively in clinical trial and are uh effective in CIDP.
- 57:00SPEAKER_09: Yeah, and we know we're learning more about the immunobiology of CIDP, understanding that it's heterogeneous disease, many different immune components at play, T cell activation, blood nerve barrier breakdown, complement activation, auto gut, autoantibody binding, macrophage binding.
- 57:16SPEAKER_09: Yeah, and we presumably think that a lot of these diseases are driven by IgG autoantibodies, although you know we don't have a recognized antibody in the majority of cases, and almost certainly not all cases are IgG autoantibody driven.
- 57:28SPEAKER_09: But if we think those things are at play, it really gives us some evidence or support to start using targeted patients.
- 57:36SPEAKER_09: And this is really kind of where the field is going, looking at therapies that specifically approach the antibody uh humoral side of the disease, clearing out pathogenic, presumably pathogenic IgG autoantibodies, you know, and therapeutics that really target different components of the immune problem, namely the complement system, are also new and emerging targets for therapies.
- 57:58SPEAKER_09: Focusing just on the FCRN antagonist, FCR is a, of course, a very important receptor that helps the body sort through different IgG proteins to decide if they should get destroyed or if they should get returned to the circulation.
- 58:11SPEAKER_09: And so IgG, by binding to the FCRN receptor, gets returned to circulation, which extends its half-life from to between 21 and 28 days.
- 58:21SPEAKER_09: Pathogenic IgG antibodies also leverage this receptor, and they can also bind to it and return to circulation.
- 58:30SPEAKER_09: What an FCRN antagonist does or inhibitor does is it outcompetes.
- 58:33SPEAKER_09: It's got a very high affinity at the FCRN receptor.
- 58:36SPEAKER_09: So it binds with a high affinity, outcompetes IgG, outcompetes IgG autoantibodies, and by blocking that receptor, subsequently moves all these IgG in order to the lysosome for catabolism and presumably those antibodies that we think are important for the disease.
- 58:52SPEAKER_09: It doesn't wipe out IgG or other antibodies, but reduces it effectively by roughly 65 to 70%.
- 58:59SPEAKER_09: We think, but don't know for sure.
- 59:01SPEAKER_09: But that's where its therapeutic benefit comes from.
- 59:04SPEAKER_02: Yeah, and whatever treatment we use, we really need objective assessment.
- 59:08SPEAKER_02: We don't rely on the patients just tell us they're doing uh good.
- 59:12SPEAKER_02: And there's recommendation from different societies uh looking at disability with the NCAT and IRODS, uh, the strengths and especially calculating the uh MRC sum score.
- 59:24SPEAKER_02: And with the gate, you can do the timed up and go, 10-minute walk tests, and so forth.
- 59:29SPEAKER_02: And for the quality of life, the chronic acquired polyonepathy patient reported index, or as it's also known as Capri.
- 59:38unknown: Great.
- 59:38SPEAKER_09: Yeah, certainly these assessments are really important to more objectively follow patients.
- 59:43SPEAKER_09: So let's go back to our polling question that we asked earlier and get your feedback on the next uh next step.
- 59:49SPEAKER_09: Um again, I won't read all of these, but let us know what you think would be the next step after hearing some of the comments and hearing our our discussions.
- 1:00:16SPEAKER_09: Right, so it sounds like we've got a lot more people thinking about moving to a different maintenance plan.
- 1:00:21SPEAKER_09: Yeah, Lesser interested in verifying things, but you know, thinking about new treatment options that are maybe a little bit more tolerated and convenient for patients or something to think about in a case like this.
- 1:00:32SPEAKER_09: So let's talk a little bit briefly about a team-based approach to CIDP management.
- 1:00:37SPEAKER_09: Shafiq, can you walk us through some of these shared decision-making approaches that we that we think about?
- 1:00:44SPEAKER_02: Yeah, Jeff, as you know, it takes a team to really optimize the care for patients with CIDP.
- 1:00:50SPEAKER_02: As you can see here, the patient is in the middle, and you have the neurology, the APP, the social worker, the pharmacist, physical therapy, occupation therapy, of course, the PCP, and also in the background, you have all the administrative staff, the clinical nursing, infusion nursing, mental health provider, authorization department, and and many, many more.
- 1:01:12SPEAKER_09: Yeah, so I think maybe we can we can wrap things up here.
- 1:01:15SPEAKER_09: I want to thank you so much, Shafiq, you know, for the discussion.
- 1:01:18SPEAKER_09: So as always, it's uh it's wonderful to talk to you.
- 1:01:21SPEAKER_09: I want to thank Luis and Carissa, Angela, uh, Ariel, and all of our clinical coordinators.
- 1:01:27SPEAKER_09: I want to thank our audience for participating in this DMET case wise program.
- 1:01:32SPEAKER_09: We have summary I could offer three SMART goals.
- 1:01:37SPEAKER_09: So again, thank you so much for attending.
- 1:01:40SPEAKER_09: Yeah, I hope you have a lovely evening.